Ser152

Site Information
PEkdGFPsGtPALNA SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 4760296

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 7 , 8 , 9 )
Disease tissue studied:	HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 5 ) , non-small cell lung cancer ( 5 ) , follicular lymphoma ( 3 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:	'stem, embryonic' ( 9 ) , breast ( 1 ) , H2009 (pulmonary) ( 5 ) , H2077 (pulmonary) ( 5 ) , H2887 (pulmonary) ( 5 ) , H322M (pulmonary) ( 5 ) , HCC366 (pulmonary) ( 5 ) , HCC78 (pulmonary) ( 5 ) , HOP62 (pulmonary) ( 5 ) , Jurkat (T lymphocyte) ( 6 , 7 , 8 ) , NCI-H1395 (pulmonary) ( 5 ) , NCI-H1568 (pulmonary) ( 5 ) , NCI-H2030 (pulmonary) ( 5 ) , NCI-H322 (pulmonary) ( 5 ) , NCI-H647 (pulmonary) ( 5 ) , SU-DHL-4 (B lymphocyte) ( 3 ) , WM239A (melanocyte) ( 2 )

References
1	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
2	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
3	Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42 24667141 Curated Info
4	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
5	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
6	Mulhern D (2011) CST Curation Set: 12678; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
7	Mulhern D (2011) CST Curation Set: 12679; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
8	Guo A (2011) CST Curation Set: 12073; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M) Curated Info
9	Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13 19664994 Curated Info